Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

Phase 1CompletedNCT01999725

Enanta Pharmaceuticals, Inc80 enrolled

Overview

The primary objective of the study is to determine the safety of single doses of orally administered EDP-788. Secondary objectives of the study are: * To describe the pharmacokinetics of EDP-788 (and its metabolite EDP-322) after single doses of orally administered drug * To estimate the bioavailability of EDP-788 capsules relative to an oral liquid suspension * To estimate the effect of co-administration of food on the absorption of EDP-788

Subjects are enrolled in successive cohorts and are randomized to receive either EDP-788 or placebo capsules. If the safety profile of the drug is acceptable, based upon review of blinded data, the cohort receiving the next higher dose will be treated. Up to 8 cohorts will be recruited. All subjects receive a single dose of study drug (EDP-788 or placebo). Subjects in Cohort C will receive a second single dose of study drug (EDP-788 or placebo) approximately 2 weeks after the first dose. The second dose will be administered as a liquid suspension rather than as a capsule formulation. The purpose of the second dose is to estimate the bioavailability of the capsule formulation relative to the suspension. Subjects in Cohort E will receive a second single dose of study drug (EDP-788 or placebo) approximately 2 weeks after the first does. The second dose will be administered with a standard test meal. The purpose of the second dose is to estimate the effect of food on absorption of EDP-788.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Safety in Normal Volunteers

Interventions

EDP-788DRUG

EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses

PlaceboDRUG

Matching placebo capsules or matching suspension

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Key Inclusion Criteria: * In good general health * BMI between 18 - 32 kg/m2 * Women must be of non-childbearing potential (surgically sterilized) * Normal electrocardiogram * Willing to abstain from strenuous physical exercise starting 3 days prior to admission to the study clinic through the 8 - 10 day post-dosing visit Key Exclusion Criteria: * Hypersensitivity to macrolide antibiotics * Abnormal laboratory values * History of gastrointestinal surgery which may interfere with drug absorption * Active Hepatitis B, Hepatitis C, or HIV infection * Use of prescription or non-prescription drugs within 14 days of study drug administration * Use of nicotine within 3 months of study drug administration

Locations (1)

PPD Phase I Clinic

Austin, Texas, United States

Outcomes

Primary Outcomes

Incidence and severity of adverse events

Time frame: From time of dosing to 8 - 10 days after receiving study drug

Secondary Outcomes

Changes from baseline in laboratory values and vital signs

Time frame: From time of dosing to 8 - 10 days after receiving study drug

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.